Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more. The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies. Provides an overview of the landscape of virotherapy for solid tumors and hematologic malignancies Reviews advances in alphaviruses, adenoviruses, vaccinia viruses and Maraba virus Presents lessons on how to improve viruses to enhance immune responses
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Contributors - p. iii 7. Chapter One: Viral vectors engineered for gene therapy - p. 1 8. Chapter Two: Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity - p. 43 9. Chapter Three: Armored modified vaccinia Ankara in cancer immunotherapy - p. 88 10. CHAPTER FOUR: Alphaviruses in cancer immunotherapy - p. 143 11. CHAPTER FIVE: Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success - p. 169 12. CHAPTER SIX: Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies - p. 190 13. CHAPTER SEVEN: Oncolytic virotherapy in lung cancer - p. 221 14. CHAPTER EIGHT: Rational selection of an ideal oncolytic virus to address current limitations in clinical translation - p. 241
Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more. The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies. Provides an overview of the landscape of virotherapy for solid tumors and hematologic malignancies Reviews advances in alphaviruses, adenoviruses, vaccinia viruses and Maraba virus Presents lessons on how to improve viruses to enhance immune responses
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Contributors - p. iii 7. Chapter One: Viral vectors engineered for gene therapy - p. 1 8. Chapter Two: Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity - p. 43 9. Chapter Three: Armored modified vaccinia Ankara in cancer immunotherapy - p. 88 10. CHAPTER FOUR: Alphaviruses in cancer immunotherapy - p. 143 11. CHAPTER FIVE: Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success - p. 169 12. CHAPTER SIX: Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies - p. 190 13. CHAPTER SEVEN: Oncolytic virotherapy in lung cancer - p. 221 14. CHAPTER EIGHT: Rational selection of an ideal oncolytic virus to address current limitations in clinical translation - p. 241
